Temat: "Mineralocorticoid receptor"

Skocz do pozycji: 1 1.

Tytuł :: Mineralocorticoid Receptor Antagonism Reduces Inflammatory Pain Measures in Mice Independent of the Receptors on Sensory Neurons.
Autorzy :: Qualls KA; Pain Research Center, Department of Anesthesiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Xie W; Pain Research Center, Department of Anesthesiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Zhang J; Pain Research Center, Department of Anesthesiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Lückemeyer DD; Pain Research Center, Department of Anesthesiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Lackey SV; Pain Research Center, Department of Anesthesiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Strong JA; Pain Research Center, Department of Anesthesiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Zhang JM; Pain Research Center, Department of Anesthesiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA. Electronic address: .; Pokaż więcej
Źródło :: Neuroscience [Neuroscience] 2024 Mar 16; Vol. 541, pp. 64-76. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji :: Journal Article
MeSH Terms :: Mineralocorticoid Receptor Antagonists*/pharmacology
Mineralocorticoid Receptor Antagonists*/therapeutic use
Low Back Pain*
Rats ; Mice ; Humans ; Animals ; Receptors, Mineralocorticoid ; Rats, Sprague-Dawley ; Sensory Receptor Cells ; Ganglia, Spinal ; Inflammation/drug therapy
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: A fluorescence chemo sensor approach for determination of finerenone in pharmaceutical formulation and human plasma: Method development and validation.
Autorzy :: Alsharif ST; Department of Pharmaceutical Sciences, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Alaqel SL; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.
Almalki AH; Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia; Addiction and Neuroscience Research Unit, Health Science Campus, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
Algarni MA; Department of Clinical Pharmacy, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
Alnemari RM; Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
H Abduljabbar M; Department of Pharmacology and Toxicology, College of Pharmacy, Taif University, Taif, 21944, Saudi Arabia.
Abdelazim AH; Department of Otolaryngology, Faculty of Medicine, Al-Azhar University, 34518, Damietta, Egypt. Electronic address: .; Pokaż więcej
Źródło :: Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy [Spectrochim Acta A Mol Biomol Spectrosc] 2024 Mar 15; Vol. 309, pp. 123836. Date of Electronic Publication: 2024 Jan 03.
Typ publikacji :: Journal Article
MeSH Terms :: Mineralocorticoid Receptor Antagonists*
Diabetes Mellitus, Type 2*
Humans ; Drug Compounding ; Naphthyridines ; Pharmaceutical Preparations
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use.
Autorzy :: Clark KAA; Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: .
Victoria-Castro AM; Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA.
Ghazi L; School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Yamamoto Y; Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA.
Coronel-Moreno C; Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA.
Kadhim BA; Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA.
Riello RJ 3rd; Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA.
O'Connor K; Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA.
Ahmad T; Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Wilson FP; Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA; Section of Nephrology and Metabolism, Yale School of Medicine, New Haven, Connecticut, USA.
Desai NR; Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA; Center for Outcome Research & Evaluation, New Haven, Connecticut, USA.; Pokaż więcej
Źródło :: JACC. Heart failure [JACC Heart Fail] 2024 Feb; Vol. 12 (2), pp. 322-332. Date of Electronic Publication: 2023 Nov 08.
Typ publikacji :: Journal Article; Pragmatic Clinical Trial; Randomized Controlled Trial
MeSH Terms :: Heart Failure*/drug therapy
Mineralocorticoid Receptor Antagonists*/therapeutic use
Humans ; Hyperkalemia/epidemiology ; Potassium/blood ; Stroke Volume
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines.
Autorzy :: Mas-Llado C; Cardiology Department, Hospital de Manacor, Spain; Health Research Institute of the Balearic Islands, Palma, Spain; Facultad de Medicina, Universitat de les Illes Balears, Palma, Spain.
Rossello X; Health Research Institute of the Balearic Islands, Palma, Spain; Facultad de Medicina, Universitat de les Illes Balears, Palma, Spain; Cardiology Department, Health Research Institute of the Balearic Islands, Hospital Universitari Son Espases, Palma, Spain; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain. Electronic address: .
González-Del-Hoyo M; Health Research Institute of the Balearic Islands, Palma, Spain.
Pocock S; London School of Hygiene and Tropical Medicine, UK.
de Werf FV; Department of Cardiovascular Sciences, University of Leuven, Belgium.
Chin CT; National Heart Centre Singapore.
Danchin N; Hôpital Européen Georges Pompidou & René Descartes University, France.
Lee SW; Queen Mary Hospital, China.
Medina J; BioPharmaceuticals Medical, AstraZeneca, Spain.
Huo Y; Beijing University First Hospital, China.
Bueno H; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; Cardiology Department, Hospital Universitario 12 de Octubre, and Instituto de Investigación i+12, Madrid, Spain; Facultad de Medicina, Universidad Complutense de Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain. Electronic address: .; Pokaż więcej
Źródło :: The American journal of medicine [Am J Med] 2024 Feb; Vol. 137 (2), pp. 137-146.e10. Date of Electronic Publication: 2023 Oct 12.
Typ publikacji :: Journal Article
MeSH Terms :: Mineralocorticoid Receptor Antagonists*/therapeutic use
Myocardial Infarction*/drug therapy
Myocardial Infarction*/prevention & control
Humans ; United States ; Secondary Prevention ; Randomized Controlled Trials as Topic ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Angiotensin Receptor Antagonists/therapeutic use ; Adrenergic beta-Antagonists/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Independent Link Between Use of Mineralocorticoid Receptor Antagonists and Muscle Wasting in Heart Failure Patients Not Receiving Renin-Angiotensin System Inhibitors.
Autorzy :: Numazawa R; Graduate School of Medicine, Sapporo Medical University.
Katano S; Division of Rehabilitation, Sapporo Medical University Hospital.; Second Division of Physical Therapy, Sapporo Medical University School of Health Science.
Yano T; Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.
Nagaoka R; Division of Rehabilitation, Sapporo Medical University Hospital.
Ohori K; Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.; Department of Cardiology, Hokkaido Cardiovascular Hospital.
Kouzu H; Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.
Honma S; Second Division of Physical Therapy, Sapporo Medical University School of Health Science.; Department of Rehabilitation, Sapporo Cardiovascular Hospital.
Fujisawa Y; Second Division of Physical Therapy, Sapporo Medical University School of Health Science.; Department of Rehabilitation, Japanese Red Cross Asahikawa Hospital.
Yamano K; Second Division of Physical Therapy, Sapporo Medical University School of Health Science.; Department of Rehabilitation, Teine Keijinkai Hospital.
Osanami A; Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.
Koyama M; Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.; Department of Public Health, Sapporo Medical University School of Medicine.
Hashimoto A; Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.; Department of Health Care Administration and Management, Sapporo Medical University School of Medicine.
Furuhashi M; Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.; Pokaż więcej
Źródło :: Circulation journal : official journal of the Japanese Circulation Society [Circ J] 2023 Dec 25; Vol. 88 (1), pp. 10-19. Date of Electronic Publication: 2023 Oct 06.
Typ publikacji :: Journal Article
MeSH Terms :: Mineralocorticoid Receptor Antagonists*/adverse effects
Heart Failure*/drug therapy
Humans ; Renin-Angiotensin System ; Antihypertensive Agents ; Enzyme Inhibitors/pharmacology ; Muscles ; Angiotensin Receptor Antagonists/adverse effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: The use of mineralocorticoid receptor antagonists for patients with heart failure with a reduced ejection fraction: A time for reassessment.
Autorzy :: Pitt B; Division of Cardiology, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Zannad F; Université de Lorraine, Inserm CIC 1433, and CHRU, Nancy, France.; Pokaż więcej
Źródło :: European journal of heart failure [Eur J Heart Fail] 2023 Dec; Vol. 25 (12), pp. 2174-2176. Date of Electronic Publication: 2023 Nov 29.
Typ publikacji :: Editorial
MeSH Terms :: Mineralocorticoid Receptor Antagonists*/therapeutic use
Mineralocorticoid Receptor Antagonists*/pharmacology
Heart Failure*/drug therapy
Humans ; Stroke Volume ; Angiotensin Receptor Antagonists/pharmacology
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Blocking aldosterone or its receptor-what is the difference?
Autorzy :: Agarwal R; Richard L Roudebush VA Medical Center, Indianapolis, IN, USA; Indiana University School of Medicine, Indianapolis, IN 46202, USA. Electronic address: .; Pokaż więcej
Źródło :: Lancet (London, England) [Lancet] 2024 Jan 27; Vol. 403 (10424), pp. 330-332. Date of Electronic Publication: 2023 Dec 15.
Typ publikacji :: Journal Article
MeSH Terms :: Aldosterone*
Mineralocorticoid Receptor Antagonists*/therapeutic use
Humans ; Spironolactone
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Initiating Mineralocorticoid Antagonists for Longstanding Heart Failure With Reduced Ejection Fraction: Better Late Than Never?
Autorzy :: Sauer AJ; Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City, Kansas City, Missouri, USA. Electronic address: .
Hsia J; University of Colorado, Aurora, Colorado, USA.; Pokaż więcej
Źródło :: Journal of the American College of Cardiology [J Am Coll Cardiol] 2023 Sep 12; Vol. 82 (11), pp. 1092-1095.
Typ publikacji :: Editorial; Comment
MeSH Terms :: Mineralocorticoid Receptor Antagonists*/pharmacology
Mineralocorticoid Receptor Antagonists*/therapeutic use
Heart Failure*/drug therapy
Humans
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE.
Autorzy :: Ferreira JP; Centre d'Investigations Cliniques Plurithématique 1433, INSERM, Université de Lorraine, Nancy, France.; F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), INSERM U1116, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.; , Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.
Blatchford JP; Elderbrook Solutions GmbH, Bietigheim-Bissingen, Germany on behalf of Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany.
Teerlink JR; Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, CA, USA.
Kosiborod MN; Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas, MO, USA.
Angermann CE; Comprehensive Heart Failure Center Würzburg, University and University Hospital Würzburg, and Department of Medicine 1, University Hospital Würzburg, Würzburg, Germany.
Biegus J; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Collins SP; Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.; Geriatric Research and Education Clinical Care, Tennessee Valley Healthcare Facility VA Medical Center, Nashville, TN, USA.
Tromp J; Saw Swee Hock School of Public Health, National University of Singapore, the National University Health System, Singapore, Singapore, Singapore.
Nassif ME; Saint Luke's Mid America Heart Institute and the University of Missouri, Kansas, MO, USA.
Psotka MA; Inova Heart and Vascular Institute, Falls Church, Virginia, VA, USA.
Comin-Colet J; Hospital Universitari de Bellvitge, University of Barcelona, IDIBELL and CIBERCV, Barcelona, Spain.
Mentz RJ; Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, NC, USA.
Brueckmann M; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.; First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.
Nordaby M; Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Ponikowski P; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Voors AA; Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Pokaż więcej
Źródło :: European journal of heart failure [Eur J Heart Fail] 2023 Oct; Vol. 25 (10), pp. 1797-1805. Date of Electronic Publication: 2023 Aug 22.
Typ publikacji :: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Mineralocorticoid Receptor Antagonists*/therapeutic use
Heart Failure*/drug therapy
Humans ; Stroke Volume ; Treatment Outcome ; Hospitalization
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Potassium canrenoate in brain-dead organ donors: a randomised controlled clinical trial protocol (CANREO-PMO).
Autorzy :: Belarif L; Department of Anesthesiology and Critical Care Medicine, CHRU de Nancy, Nancy, France.
Girerd S; Department of Nephrology, CHRU de Nancy, Nancy, France.; Centre d'Investigations Cliniques-Plurithématique 1433 (CIC-P), INI-CRCT-Cardiovascular and Renal Clinical Trialists, CHRU de Nancy, Nancy, France.
Jaisser F; Centre d'Investigations Cliniques-Plurithématique 1433 (CIC-P), INI-CRCT-Cardiovascular and Renal Clinical Trialists, CHRU de Nancy, Nancy, France.; INSERM UMRS 1138, Centre de Recherche des Cordeliers, Sorbonne Universite, Paris, France.
Lepage X; Centre d'Investigations Cliniques-Plurithématique 1433 (CIC-P), INI-CRCT-Cardiovascular and Renal Clinical Trialists, CHRU de Nancy, Nancy, France.
Merckle L; Centre d'Investigations Cliniques-Plurithématique 1433 (CIC-P), INI-CRCT-Cardiovascular and Renal Clinical Trialists, CHRU de Nancy, Nancy, France.
Duarte K; Centre d'Investigations Cliniques-Plurithématique 1433 (CIC-P), INI-CRCT-Cardiovascular and Renal Clinical Trialists, CHRU de Nancy, Nancy, France.
Girerd N; Centre d'Investigations Cliniques-Plurithématique 1433 (CIC-P), INI-CRCT-Cardiovascular and Renal Clinical Trialists, CHRU de Nancy, Nancy, France.
Guerci P; Department of Anesthesiology and Critical Care Medicine, CHRU de Nancy, Nancy, France .; INSERM U1116, DCAC, University of Lorraine, Nancy, France.; Pokaż więcej
Źródło :: BMJ open [BMJ Open] 2023 Oct 11; Vol. 13 (10), pp. e073831. Date of Electronic Publication: 2023 Oct 11.
Typ publikacji :: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Canrenoic Acid*
Kidney Transplantation*
Mineralocorticoid Receptor Antagonists*/therapeutic use
Humans ; Brain ; Brain Death ; Randomized Controlled Trials as Topic ; Renal Dialysis ; Renal Insufficiency, Chronic/drug therapy ; Renal Insufficiency, Chronic/surgery ; Tissue Donors ; Double-Blind Method ; Myocardial Reperfusion Injury/prevention & control
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Non-steroidal mineralocorticoid receptor antagonists in heart failure.
Autorzy :: Filippatos G; Department of Cardiology, Athens University Hospital Attikon, National and Kapodistrian University of Athens Medical School, Athens, Greece. .
Farmakis D; Department of Cardiology, Athens University Hospital Attikon, National and Kapodistrian University of Athens Medical School, Athens, Greece.; Pokaż więcej
Źródło :: Nature reviews. Cardiology [Nat Rev Cardiol] 2023 Oct; Vol. 20 (10), pp. 645-646.
Typ publikacji :: Journal Article
MeSH Terms :: Mineralocorticoid Receptor Antagonists*/therapeutic use
Heart Failure*/drug therapy
Humans
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
Autorzy :: Banerjee M; Department of Endocrinology, Institute of Postgraduate Medical Education and Research, 244, AJC Bose Rd, Kolkata, West Bengal 700020, India.
Maisnam I; Department of Endocrinology, Institute of Postgraduate Medical Education and Research, 244, AJC Bose Rd, Kolkata, West Bengal 700020, India.
Pal R; Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India.
Mukhopadhyay S; Department of Endocrinology, Institute of Postgraduate Medical Education and Research, 244, AJC Bose Rd, Kolkata, West Bengal 700020, India.; Pokaż więcej
Źródło :: European heart journal [Eur Heart J] 2023 Oct 01; Vol. 44 (37), pp. 3686-3696.
Typ publikacji :: Meta-Analysis; Journal Article
MeSH Terms :: Heart Failure*
Hyperkalemia*/chemically induced
Mineralocorticoid Receptor Antagonists*/therapeutic use
Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use
Humans ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Randomized Controlled Trials as Topic
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Personalized Treatment of Patients With Primary Aldosteronism.
Autorzy :: Obeid H; Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan.
Chen Cardenas SM; Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Khairi S; Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan.
Turcu AF; Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan. Electronic address: .; Pokaż więcej
Źródło :: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists [Endocr Pract] 2023 Jun; Vol. 29 (6), pp. 484-490. Date of Electronic Publication: 2022 Oct 20.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Hyperaldosteronism*/therapy
Receptors, Mineralocorticoid*/therapeutic use
Mineralocorticoid Receptor Antagonists*/therapeutic use
Patient-Centered Care ; Hypertension/etiology ; Renin ; Precision Medicine ; Aldosterone
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients.
Autorzy :: Morita R; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Tsukamoto S; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Obata S; Department of Medicine, Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Yamada T; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.; Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Uneda K; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.; Department of Kampo Medicine, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Japan.
Uehara T; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Rehman ME; Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Azushima K; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Wakui H; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Tamura K; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.; Pokaż więcej
Źródło :: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 May; Vol. 25 (5), pp. 1271-1279. Date of Electronic Publication: 2023 Feb 02.
Typ publikacji :: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :: Albuminuria*/drug therapy
Albuminuria*/etiology
Albuminuria*/prevention & control
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Mineralocorticoid Receptor Antagonists*/therapeutic use
Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use
Humans ; Creatinine ; Drug Therapy, Combination
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Effects of the mineralocorticoid receptor antagonist eplerenone in experimental autoimmune encephalomyelitis.
Autorzy :: Alvarez Quintero GS; Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental-CONICET, Obligado 2490, 1428 Buenos Aires, Argentina.
Lima A; Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental-CONICET, Obligado 2490, 1428 Buenos Aires, Argentina.
Roig P; Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental-CONICET, Obligado 2490, 1428 Buenos Aires, Argentina.
Meyer M; Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental-CONICET, Obligado 2490, 1428 Buenos Aires, Argentina.
de Kloet ER; Department of Clinical Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.
De Nicola AF; Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental-CONICET, Obligado 2490, 1428 Buenos Aires, Argentina; Department of Human Biochemistry, University of Buenos Aires, Paraguay 2155, 1121 Buenos Aires, Argentina.
Garay LI; Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental-CONICET, Obligado 2490, 1428 Buenos Aires, Argentina; Department of Human Biochemistry, University of Buenos Aires, Paraguay 2155, 1121 Buenos Aires, Argentina. Electronic address: .; Pokaż więcej
Źródło :: The Journal of steroid biochemistry and molecular biology [J Steroid Biochem Mol Biol] 2024 Apr; Vol. 238, pp. 106461. Date of Electronic Publication: 2024 Jan 12.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Encephalomyelitis, Autoimmune, Experimental*/drug therapy
Encephalomyelitis, Autoimmune, Experimental*/metabolism
Mice ; Animals ; Eplerenone/pharmacology ; Eplerenone/therapeutic use ; Mineralocorticoid Receptor Antagonists/pharmacology ; Mineralocorticoid Receptor Antagonists/therapeutic use ; Neuroinflammatory Diseases ; Spinal Cord/pathology ; Mice, Inbred C57BL
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease.
Autorzy :: Bayne S; Drake University College of Pharmacy and Health Sciences, Des Moines, IA, 50311, USA.
LeFevre J; Drake University College of Pharmacy and Health Sciences, Des Moines, IA, 50311, USA.
Olstinske K; Drake University College of Pharmacy and Health Sciences, Des Moines, IA, 50311, USA.
Ravindran S; Reagents and Assay Development, R&D, BD Biosciences, San Jose, CA, 95131, USA.
Munusamy S; Department of Pharmaceutical and Administrative Sciences, Drake University College of Pharmacy and Health Sciences, Des Moines, IA, 50311, USA.; Pokaż więcej
Źródło :: Advanced biology [Adv Biol (Weinh)] 2024 Mar; Vol. 8 (3), pp. e2300496. Date of Electronic Publication: 2023 Dec 08.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Diabetic Nephropathies*/drug therapy
Diabetic Nephropathies*/prevention & control
Diabetic Nephropathies*/etiology
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Humans ; Mineralocorticoid Receptor Antagonists/pharmacology ; Mineralocorticoid Receptor Antagonists/therapeutic use ; Angiotensin Receptor Antagonists/pharmacology ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Aldosterone and aldosterone synthase inhibitors in cardiorenal disease.
Autorzy :: Verma S; Division of Cardiac Surgery, St. Michael's Hospital-Unity Health Toronto, Toronto, Ontario, Canada.; Department of Surgery, University of Toronto, Toronto, Ontario, Canada.; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Pandey A; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Pandey AK; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Butler J; Baylor Scott and White Research Institute, Dallas, Texas, United States.; University of Mississippi, Jackson, Mississippi, United States.
Lee JS; LJ Biosciences, LLC, Rockville, Maryland, United States.; PhaseBio Pharmaceuticals, Malvern, Pennsylvania, United States.
Teoh H; Division of Cardiac Surgery, St. Michael's Hospital-Unity Health Toronto, Toronto, Ontario, Canada.; Division of Endocrinology and Metabolism, St. Michael's Hospital-Unity Health Toronto, Toronto, Ontario, Canada.
Mazer CD; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.; Department of Anesthesia, St. Michael's Hospital-Unity Health Toronto, Toronto, Ontario, Canada.; Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada.; Department of Physiology, University of Toronto, Toronto, Ontario, Canada.
Kosiborod MN; Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States.; University of Missouri-Kansas City, Kansas City, Missouri, United States.
Cosentino F; Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
Anker SD; Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
Connelly KA; Department of Physiology, University of Toronto, Toronto, Ontario, Canada.; Division of Cardiology, St. Michael's Hospital-Unity Health Toronto, Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Bhatt DL; Mount Sinai Fuster Heart, Icahn School of Medicine at Mount Sinai Health System, New York, New York, United States.; Pokaż więcej
Źródło :: American journal of physiology. Heart and circulatory physiology [Am J Physiol Heart Circ Physiol] 2024 Mar 01; Vol. 326 (3), pp. H670-H688. Date of Electronic Publication: 2023 Dec 22.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Hypertension, Renal*/drug therapy
Heart Diseases*/drug therapy
Nephritis*
Humans ; Cytochrome P-450 CYP11B2/genetics ; Cytochrome P-450 CYP11B2/metabolism ; Aldosterone/pharmacology ; Hypothalamo-Hypophyseal System/metabolism ; Pituitary-Adrenal System/metabolism ; Renin-Angiotensin System ; Mineralocorticoid Receptor Antagonists/therapeutic use ; Mineralocorticoid Receptor Antagonists/pharmacology
SCR Disease Name :: Hypertensive Nephropathy
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: The influence of pharmacological mineralocorticoid and glucocorticoid receptor blockade on the cortisol response to psychological stress.
Autorzy :: Deuter CE; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany. Electronic address: .
Kaczmarczyk M; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany.
Hellmann-Regen J; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany; DZPG (German Center for Mental Health), Germany.
Kuehl LK; Medical School Berlin, Germany.
Wingenfeld K; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany; DZPG (German Center for Mental Health), Germany.
Otte C; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany; DZPG (German Center for Mental Health), Germany.; Pokaż więcej
Źródło :: Progress in neuro-psychopharmacology & biological psychiatry [Prog Neuropsychopharmacol Biol Psychiatry] 2024 Feb 08; Vol. 129, pp. 110905. Date of Electronic Publication: 2023 Dec 02.
Typ publikacji :: Journal Article
MeSH Terms :: Spironolactone*/pharmacology
Spironolactone*/metabolism
Mifepristone*/pharmacology
Mifepristone*/metabolism
Male ; Humans ; Hydrocortisone/metabolism ; Mineralocorticoids/metabolism ; Mineralocorticoids/pharmacology ; Receptors, Glucocorticoid/metabolism ; Mineralocorticoid Receptor Antagonists/pharmacology ; Mineralocorticoid Receptor Antagonists/metabolism ; Hypothalamo-Hypophyseal System/metabolism ; Receptors, Mineralocorticoid/metabolism ; Stress, Psychological/drug therapy
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists.
Autorzy :: Savarese G; Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. .; Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden. .
Lindberg F; Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Filippatos G; Department of Cardiology, University Hospital Attikon, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Butler J; Baylor Scott and White Research Institute, Dallas, TX, USA.; Department of Internal Medicine, University of Mississippi, Jackson, MS, USA.
Anker SD; Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany. .; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland. .; Pokaż więcej
Źródło :: Diabetologia [Diabetologia] 2024 Feb; Vol. 67 (2), pp. 246-262. Date of Electronic Publication: 2023 Dec 21.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Diabetic Nephropathies*/drug therapy
Heart Failure*/drug therapy
Humans ; Mineralocorticoid Receptor Antagonists/adverse effects ; Mineralocorticoids/therapeutic use ; Naphthyridines/pharmacology ; Naphthyridines/therapeutic use ; Receptors, Mineralocorticoid/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence.
Autorzy :: Sayour NV; Department of Pharmacology and Pharmacotherapy, Semmelweis University, H-1085 Budapest, Üllői út 26, Hungary.; HCEMM-SU Cardiometabolic Immunology Research Group, H-1089 Budapest, Nagyvárad tér 4, Hungary.; MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group, H-1089 Budapest, Nagyvárad tér 4, Hungary.
Paál ÁM; Department of Pharmacology and Pharmacotherapy, Semmelweis University, H-1085 Budapest, Üllői út 26, Hungary.
Ameri P; Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Italian IRCCS Cardiology Network, Genova, Italy.; Department of Internal Medicine, University of Genova, Genova, Italy.
Meijers WC; Department of Cardiology, Thorax Center, Erasmus University Medical Center, Rotterdam, The Netherlands.
Minotti G; University Campus Bio-Medico, Via Álvaro del Portillo, 21, 00128 Rome, Italy.
Andreadou I; Laboratory of Pharmacology, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Lombardo A; Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.; Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Camilli M; Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.; Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Drexel H; Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT), Carinagasse 47, A-6800 Feldkirch, Austria.
Grove EL; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Dan GA; Carol Davila University of Medicine and Pharmacy, Colentina University Hospital, Bucharest, Romania.; Cardiology Department, Colentina Clinical Hospital, Bucharest, Romania.
Ivanescu A; Carol Davila University of Medicine and Pharmacy, Colentina University Hospital, Bucharest, Romania.; Cardiology Department, Colentina Clinical Hospital, Bucharest, Romania.
Semb AG; Division of Research and Innovation, REMEDY-Centre for Treatment of Rheumatic and Musculoskeletal Diseases, Diakonhjemmet Hospital, Oslo, Norway.
Savarese G; Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.; Heart and Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.
Dobrev D; Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany.; Department of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Montréal, QC, Canada.; Department of Integrative Physiology, Baylor College of Medicine, Houston, TX, USA.
Crea F; Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.; Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Kaski JC; Molecular and Clinical Sciences Research Institute, St. George's University of London, London, United Kingdom.
de Boer RA; Department of Cardiology, Thorax Center, Erasmus University Medical Center, Rotterdam, The Netherlands.
Ferdinandy P; Department of Pharmacology and Pharmacotherapy, Semmelweis University, H-1085 Budapest, Üllői út 26, Hungary.; Pharmahungary Group, Szeged, Hungary.; MTA-SE System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
Varga ZV; Department of Pharmacology and Pharmacotherapy, Semmelweis University, H-1085 Budapest, Üllői út 26, Hungary.; HCEMM-SU Cardiometabolic Immunology Research Group, H-1089 Budapest, Nagyvárad tér 4, Hungary.; MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group, H-1089 Budapest, Nagyvárad tér 4, Hungary.; Pokaż więcej
Źródło :: European heart journal [Eur Heart J] 2024 Apr 07; Vol. 45 (14), pp. 1224-1240.
Typ publikacji :: Review; Journal Article
MeSH Terms :: Heart Failure*
Neoplasms*/drug therapy
Humans ; Stroke Volume ; Angiotensin Receptor Antagonists/therapeutic use ; Adrenergic beta-Antagonists/therapeutic use ; Mineralocorticoid Receptor Antagonists/therapeutic use
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaBiblioteka UWSB Merito Chorzów

Wyszukujesz frazę ""Mineralocorticoid receptor"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Dostawca treści

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Hasło geograficzne